Jermendy György
Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi út 89-91. 1106.
Orv Hetil. 2011 Sep 11;152(37):1471-6. doi: 10.1556/OH.2011.29207.
Nearly 90% of the diabetic patients are suffering of type 2 diabetes while approximately 60-65% of patients with type 2 diabetes are treated with oral antidiabetic drugs. In the last couple of years a new treatment option, namely incretin-based therapy, became available. The dipeptidyl-peptidase-4-inhibitors (gliptins) are designated as incretin enhancers. Using gliptins, sustained glycemic control can be achieved without gaining weight and increasing the risk of hypoglycemia. All gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin) can be used as tablets without a need for dose titration. For treating patients with type 2 diabetes, gliptins can primarily be used in combination with metformin.
近90%的糖尿病患者患有2型糖尿病，而约60 - 65%的2型糖尿病患者接受口服抗糖尿病药物治疗。在过去几年中，一种新的治疗选择，即基于肠促胰岛素的疗法出现了。二肽基肽酶-4抑制剂（格列汀类）被指定为肠促胰岛素增强剂。使用格列汀类药物，可以在不增加体重和低血糖风险的情况下实现持续的血糖控制。所有格列汀类药物（西他列汀、维格列汀、沙格列汀、利格列汀）都可以制成片剂使用，无需剂量滴定。对于治疗2型糖尿病患者，格列汀类药物主要可与二甲双胍联合使用。
